Loading…
← CockpitCompetitor Analysis › NUTX Nutex Health IncOpen in the cockpit ↗

Nutex Health IncNUTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Operator of micro-hospitals and freestanding emergency rooms providing emergency and outpatient care in local communities.

Momentum strong 72
Mkt cap
$1.19B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$27.5M
20-day average traded
Fwd P/E
6.5×
forward earnings
ROIC−WACC
+24.7 pp
WACC 7.7%
Hurdle
-271 pp
Req g minus delivered
Next earnings
106 days
4 Mar 2027
Close · USD$172.74
1D-1.0%
1W-8.7%
1M-13.2%
3M-8.4%
6M+42.1%
YTD+4.9%
1Y+66.2%
ATR %7.5%
Beta1.67
52w lowhigh23.6% off high

What Nutex Health does

Operator of micro-hospitals and freestanding emergency rooms providing emergency and outpatient care in local communities.

Bills each patient's insurer for emergency visits, and much of its income comes from out-of-network claims, which pay more than contracted rates but are negotiated or disputed afterwards, so collections vary. Facilities are concentrated in Texas. It became public through a 2022 merger with Clinigence Holdings.

Products and services

  • Freestanding emergency room services
  • Micro-hospital inpatient services

Customers

  • Emergency care patients
  • Local communities
  • Health insurers (out-of-network billing)

Where it sits in the supply chain

  • Health care services
  • Micro-hospital/emergency care…
  • Freestanding emergency rooms…

What could go right

  • Underserved-market emergency care demand
  • Facility expansion into new states

What could go wrong

  • Regulatory/billing-practice scrutiny (surprise billing)
  • Reimbursement policy risk

Moat: narrow (regulatory licence, distribution). State-licensed micro-hospital model provides emergency access in underserved areas, though model draws billing scrutiny.

Headquarters: Houston, Texas · Founded: 2011 · Employees: 944

Named competitors

Nutex Health at a glance

Size Nutex Health (NUTX) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.19B, the 2128th largest of 3,085 United States companies the cockpit tracks. Shares closed at $172.74 on 18 Nov 2026.

Performance Over six months the shares gained 42.1%, against +12.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 18.8% over the last twelve months (peer median +7.9%); the operating margin is 39.0% (peer median 3.5%).

Valuation It trades at 6.5× forward earnings against a peer median of 25.3× (cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +253%, so the hurdle is -271 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 24.7 points above its cost of capital (7.7% WACC).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026NUTX 145Peer median 113
Six months, rebased to 100: Nutex Health against the median of its 20 peers (local-currency closes).

Nutex Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$797M$875M$480M$248M$219M
Revenue growth—+82%+94%+13%—
Gross profit$381M$444M$196M$34.8M$13.5M
EBITDA$333M$296M$157M$16.3M$8.62M
Net income$165M$70.8M$52.1M-$45.8M-$425M
Free cash flow$248M$246M$20.8M-$8.24M$36.0M
Capital expenditure$10.4M$2.53M$2.30M$9.50M$14.6M
Total debt$365M$351M$340M$276M$267M

Quarterly statements and history in the cockpit →

Nutex Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%GDRXMETROPOLISOPKPNTGDIACLARILMRI1833688315AHCOUSPH4544REGTDOC4694AGLWGSAMBEASNDAPSNLNUTX6-month return →1-month return →
Up and to the right = strong over both horizons. Nutex Health is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×GDRXMETROPOLISPNTGDIACLARILMRI1833688315USPH4544REG4694AGLWGSAMBEANUTXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nutex Health is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%GDRXMETROPOLISPNTGDIATDOCNUTXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nutex Health is the large dot.

Nutex Health competitors and peer comparison

Head to head with its named competitors (NUTX vs HCA vs CYH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Nutex Health NUTX$1.19B+42%-19%39%6.5×-18.0%
HCA Healthcare HCA$99.5B+20%+6%15%15.6×3.1%
Community Health Systems CYHn/a-34%n/an/an/an/a

How Nutex Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nutex Health against its 20 peers (data as of 18 Nov 2026)
MeasureNUTXPeer medianRank in peer set
1-month return-13.2%+1.3%3rd lowest of 21
6-month return+42.1%+12.3%4th highest of 21
Distance from 52-week high-23.6%-22.4%11th highest of 21
Revenue growth (TTM)-18.8%+7.9%2nd lowest of 21
Operating margin39.0%3.5%highest of 21
Forward P/E6.5×25.3×cheapest of 16
Growth the price implies (Req g, 7 yrs)-18.0%8.5%least demanding of 15
Growth delivered (Del g)+253.5%+9.4%highest of 15
Hurdle (Req g minus delivered)-271.5 pp-0.4 ppleast demanding of 15
ROIC minus cost of capital+24.7 pp-3.8 pphighest of 19
EV / EBITDA4.2×10.1×cheapest of 15
Net debt / EBITDA0.3×2.0×5th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a

Questions

Who are Nutex Health's main competitors?
Named competitors: HCA Healthcare (HCA), Community Health Systems (CYH). The cockpit's measured peer set (industry) also includes GoodRx (GDRX), Metropolis Healthcare (METROPOLIS.NS), OPKO Health (OPK), Pennant (PNTG), Diagnostyka (DIA.WA), Clariane (CLARI.PA).
Is Nutex Health expensive compared with its peers?
On forward p/e it trades at 6.5× against a peer median of 25.3×, cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -18% a year for seven years (Req g). Recent delivered growth is +253%, so the hurdle is -271 pp: the price already allows for a slowdown.
How has Nutex Health stock performed?
Over six months to 18 Nov 2026 the shares returned +42.1% against +12.3% for the median peer; over one year +66.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.